This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Principal Investigator
Anne-Marie Langevin
Virginia Diaz
210-562-9149
diazvr@uthscsa.edu
Jaclyn Hung
210-450-5358
hungj@uthscsa.edu
| Arm | Description | Intervention |
|---|---|---|
Arm A (imatinib mesylate, EsPhALL chemotherapy) | See Detailed Description | Given IV Other names:
Given IV Other names:
Given IV Other names:
Given IV Other names:
Given IV Other names:
|
Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT) | See Detailed Description | Given IV Other names:
Given IV Other names:
Given IV Other names:
Given IV Other names:
Given IV Other names:
|
Arm B (imatinib mesylate, COG/BFM chemotherapy) | See Detailed Description. | Given IV Other names:
Given IV Other names:
Correlative studies Given IT Other names:
Given IV Other names:
Ancillary studies Given PO Other names:
Given IV, SC, or IT Other names:
Given PO or IV Other names:
Given IV Other names:
Given PO Other names:
Given PO or IV Other names:
Given PO Other names:
|